Utility of serum eosinophil-derived neurotoxin (EDN) measurement by ELISA in young children with asthma

Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Kwon, Eun-Mi

doi:10.1016/j.alit.2016.05.008

Cited by 24 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike the other three, EDN has an isoelectronic point of 8.3, which is close to neutral; therefore, it is possible to measure accurately and reproducibly in the blood. 35) In a previous study, we compared the concentrations of serum EDN to asthma symptom scores in preschool children. 36) Serum EDN levels were the highest in children with acute asthma, followed by those with stable asthma and those in the control group, and the differences among the three groups were significant.…”

Section: Preschool Children With Asthma or Recurrent Wheezingmentioning

confidence: 99%

“…Using 44.2 ng/mL (median+1SD) as the cut off for an elevated EDN level compared to those found in Controls, the sensitivity was 81.3%, the specificity was 87.1%, the positive predictive value (PPV) of EDN level for asthma 90.7 %, and the negative predictive value (NPV) was 75.0%. 35) Another recent study compared the effects of montelukast and 0.5-mg budesonide inhalation suspension therapy for 12 weeks in symptomatic preschool children with asthma and serum EDN levels ≥53 ng/mL. 37) During the study period, asthma control days increased in both groups and there was no significant intergroup difference.…”

Section: Preschool Children With Asthma or Recurrent Wheezingmentioning

confidence: 99%

“…EDN is one of four major proteins secreted by activated eosinophils together with ECP, major basic protein, and eosinophil peroxidase. Unlike the other three, EDN has an isoelectronic point of 8.3, which is close to neutral; therefore, it is possible to measure accurately and reproducibly in the blood [ 35 ]. In a previous study, we compared the concentrations of serum EDN to asthma symptom scores in preschool children [ 36 ].…”

Section: Clinical Use Of Montelukast In Children With Asthmamentioning

confidence: 99%

See 2 more Smart Citations

Montelukast use over the past 20 years: monitoring of its effects and safety issues

Lee

Kim

2020

Clin Exp Pediatr

Self Cite

View full text Add to dashboard Cite

Montelukast, a leukotriene receptor antagonist, was launched 20 years ago in Korea. It is recommended as an alternative treatment for asthma in children with mild persistent symptoms or as an add-on treatment to existing low-dose inhaled corticosteroids (ICSs) in children who require additional treatment. However, in the real-world setting, many doctors and patients prefer montelukast over ICSs despite their lower efficacy. Although montelukast is considered to be a safe drug, there are concerns regarding adverse drug reactions, including the rare occurrence of Churg-Strauss syndrome and, despite insufficient data, the possibility of neuropsychiatric events such as anxiety, depression, sleep disturbance, and suicidality. This review identified that montelukast has significantly contributed to asthma control over the past 20 years in Korea and has been critical for reducing asthma severity, especially early wheezing and disease control. Our findings suggest that the effects of montelukast treatment can be monitored by measuring serum eosinophilderived neurotoxin levels.

show abstract

Section: Preschool Children With Asthma or Recurrent Wheezingmentioning

confidence: 99%

Section: Preschool Children With Asthma or Recurrent Wheezingmentioning

confidence: 99%

Section: Clinical Use Of Montelukast In Children With Asthmamentioning

confidence: 99%

See 1 more Smart Citation

Montelukast use over the past 20 years: monitoring of its effects and safety issues

Lee

Kim

2020

Clin Exp Pediatr

Self Cite

View full text Add to dashboard Cite

show abstract

“… 27 31 Using a more accurate biomarker for eosinophilic inflammation in the management of asthma may produce even better results. 32 33 It has been suggested by many studies that EDN is a more accurate biomarker than eosinophil numbers or percentages. 11 12 22 32 Future studies of EDN as a biomarker for the diagnosis, treatment and monitoring of conditions associated with airway inflammation — such as recurrent wheeze, multiple-trigger wheeze and asthma — are needed.…”

Section: Discussionmentioning

confidence: 99%

Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma

Kim

Callaway

Park

et al. 2018

Allergy Asthma Immunol Res

Self Cite

View full text Add to dashboard Cite

PurposeSeveral markers for eosinophilic inflammation have been proposed to predict response to asthma treatment. However, definitive criteria for treatment decisions have not yet been established. We investigate a potentially useful relatively non-invasive biomarker, eosinophil-derived neurotoxin (EDN), to predict favorable responses to budesonide or montelukast, common treatment for children with asthma.MethodsYoung children (1 to 6 years old) were enrolled in this randomized, parallel, 2-group, open-label trial. Criteria for eligibility included: 1) being symptomatic during the run-in period; and 2) having a serum EDN (sEDN) level ≥ 53 ng/mL, with positive specific immunoglobulin E to house dust mite. Eligible patients were randomly placed into 2 groups: the BIS group received budesonide inhalation suspension (BIS) 0.5 mg once daily; the MONT group received montelukast 4 mg once daily. Ineligible patients were invited to receive montelukast 4 mg once daily (OBS group). Treatment period was 12 weeks.ResultsAsthma control days increased significantly in the BIS and MONT groups (P < 0.000) over the 12-week study period. There was no significant change in sEDN in the BIS group but there was a significant decrease in the MONT group (P < 0.000). Patients in the OBS group with high EDN levels (< 53 ng/mL) showed a significant decrease due to MONT treatment (P = 0.023). Rescue medication usage significantly decreased in the BIS and MONT groups (P < 0.000).ConclusionsEDN is a useful relatively non-invasive biomarker for predicting responses to montelukast and budesonide treatment of preschool children with beta2-agonist responsive recurrent wheeze and multiple-trigger wheeze (Trial registry at UMIN Clinical Trials Registry, UMIN000008335).

show abstract

“…EDN concentration was studied in plasma, urine, and stools in a number of inflammatory diseases, including asthma and atopic dermatitis [51][52][53]. In terms of FA, Ada et al studied a group of children diagnosed with FPIES, in whom the level of EDN in stools was tested before and after oral food challenge.…”

Section: Eosinophil-derived Neurotoxinmentioning

confidence: 99%

Biomarkers of intestinal epithelial damage in children with food allergies

Rycyk¹,

Lebensztejn²,

Cudowska³

2019

polp

View full text Add to dashboard Cite

Food allergy has a significant negative impact on patients and their families, and it has become an important public health problem. Currently used diagnostic methods, such as skin prick tests (SPT) and determination of specific immunoglobulins E (sIgE), present limited sensitivity and specificity. Therefore, new tools are expected to improve the accuracy of the diagnostic work-up. A recent hypothesis of allergic reactions indicates a primary role of dysregulation of the epithelial barrier, which pioneers the role of biomarkers of intestinal damage in food allergy. The objective of this paper is to present the currently most promising biomarkers for the diagnosis, prognosis, and management of food allergy in children.

show abstract

Utility of serum eosinophil-derived neurotoxin (EDN) measurement by ELISA in young children with asthma

Cited by 24 publications

References 15 publications

Montelukast use over the past 20 years: monitoring of its effects and safety issues

Montelukast use over the past 20 years: monitoring of its effects and safety issues

Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma

Biomarkers of intestinal epithelial damage in children with food allergies

Contact Info

Product

Resources

About